



11
Amend + B

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Keating et al.

Serial No: 09/554,996

Filed: May 24, 2000

For: Elastin-Based Compositions

Attorney Docket No. HYDR-P01-002

Art Unit: 1632

Examiner: S. Chen

TECH CENTER 1600/2900

NOV 22 2002


RECEIVED

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents Washington, D.C. 20231 on the date indicated below:

November 12, 2002

Date of Signature
and of Mail Deposit


Brent LaBarge

Commissioner for Patents
Washington, D.C. 20231

REPLY UNDER 37 CFR 1.111

Sir:

This amendment is being filed in reply to the outstanding Office Action, mailed May 10, 2002, in connection with the above application. Please enter the following amendments:

In the claims:

For the convenience of the Examiner, all claims being examined, whether or not amended, are presented below.

1. (Amended) A pharmaceutical composition that provides an elastin-based composition for localized delivery in vivo, said elastin-based composition comprising a polypeptide having an amino acid sequence at least 80% identical to SEQ ID NO: 2, SEQ ID NO: 3, or a peptide fragment thereof including at least one hexameric sequence represented by SEQ ID NO: 1, wherein said elastin-based composition is attached to a biocompatible support or dissolved in a biocompatible matrix and has one or more biological activities selected from the group consisting of: